Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 04:00PM ET
3.35
Dollar change
-0.78
Percentage change
-18.89
%
IndexRUT P/E- EPS (ttm)-1.10 Insider Own26.07% Shs Outstand26.79M Perf Week-11.84%
Market Cap90.01M Forward P/E- EPS next Y-1.18 Insider Trans-3.25% Shs Float19.86M Perf Month-44.99%
Income-28.30M PEG- EPS next Q-0.22 Inst Own21.66% Short Float9.47% Perf Quarter-71.22%
Sales0.17M P/S529.50 EPS this Y24.78% Inst Trans- Short Ratio14.05 Perf Half Y-83.26%
Book/sh0.73 P/B4.61 EPS next Y-35.24% ROA-169.32% Short Interest1.88M Perf Year-88.33%
Cash/sh0.86 P/C3.88 EPS next 5Y- ROE- 52W Range3.42 - 40.98 Perf YTD-76.09%
Dividend Est.- P/FCF- EPS past 5Y-23.84% ROI-132.61% 52W High-91.83% Beta-1.31
Dividend TTM- Quick Ratio3.69 Sales past 5Y-24.62% Gross Margin-498.82% 52W Low-2.05% ATR (14)0.53
Dividend Ex-Date- Current Ratio3.69 EPS Y/Y TTM-412.24% Oper. Margin-14214.71% RSI (14)27.67 Volatility15.11% 11.36%
Employees23 Debt/Eq0.13 Sales Y/Y TTM-98.46% Profit Margin-16645.29% Recom1.00 Target Price26.00
Option/ShortNo / Yes LT Debt/Eq0.10 EPS Q/Q-77.51% Payout- Rel Volume1.96 Prev Close4.13
Sales Surprise- EPS Surprise-33.33% Sales Q/Q-100.00% EarningsApr 01 BMO Avg Volume133.88K Price3.35
SMA20-30.72% SMA50-46.30% SMA200-78.72% Trades Volume262,721 Change-18.89%
Date Action Analyst Rating Change Price Target Change
Nov-27-23Initiated H.C. Wainwright Buy $35
Sep-12-23Initiated Maxim Group Buy $40
Feb-15-23Initiated The Benchmark Company Speculative Buy $10
Apr-05-24 09:35AM
Apr-04-24 12:00PM
Apr-02-24 07:52AM
Apr-01-24 07:00AM
Dec-15-23 03:01PM
07:00AM Loading…
Nov-27-23 07:00AM
Nov-14-23 05:50PM
Oct-20-23 01:22PM
Oct-11-23 09:00AM
Sep-19-23 03:01PM
Sep-15-23 03:03PM
Sep-14-23 01:21PM
07:00AM
Sep-07-23 04:01PM
Aug-28-23 07:00AM
07:00AM Loading…
Aug-14-23 07:00AM
Aug-02-23 04:00PM
01:08AM
Jul-28-23 10:54AM
Jul-20-23 04:45PM
Jul-10-23 07:00AM
Jun-29-23 07:00AM
Jun-22-23 07:00AM
Jun-12-23 07:00AM
Jun-01-23 05:19PM
May-25-23 04:01PM
May-15-23 07:00AM
Mar-23-23 07:00AM
Jan-25-23 09:00PM
Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szalay Aladar10% OwnerApr 17 '24Sale3.7122,73784,4251,300,125Apr 18 05:00 PM
Szalay Aladar10% OwnerApr 16 '24Sale3.5348,683171,8021,322,862Apr 18 05:00 PM
Yu YongVP, Clinical Trial OperationsDec 15 '23Sale13.1632,535428,1800Dec 18 04:15 PM
Thomas JohnDirectorDec 13 '23Sale13.389,000120,387463,460Dec 14 08:58 PM
Tyree James LDirectorDec 13 '23Sale13.229,000118,9693,460Dec 14 08:59 PM
Yu YongVP, Clinical Trial OperationsDec 07 '23Sale11.8536,800435,99532,535Dec 08 05:57 PM
Yu YongVP, Clinical Trial OperationsNov 21 '23Sale10.2618,665191,55569,335Nov 22 04:15 PM
Szalay Aladar10% OwnerOct 25 '23Sale19.405,704110,6381,371,545Oct 26 05:07 PM
Yu YongVP, Clinical Trial OperationsOct 24 '23Option Exercise6.005,20031,200111,335Oct 25 04:15 PM
Yu YongVP, Clinical Trial OperationsOct 24 '23Sale19.115,20099,351106,135Oct 25 04:15 PM
Szalay Aladar10% OwnerOct 23 '23Sale19.9749,987998,3651,377,249Oct 25 04:51 PM
Thomas JohnDirectorOct 16 '23Sale20.713,33369,038472,460Oct 16 06:39 PM
Yu YongVP, Clinical Trial OperationsOct 10 '23Option Exercise6.005,20031,200111,335Oct 11 04:10 PM
Yu YongVP, Clinical Trial OperationsOct 10 '23Sale22.015,200114,462106,135Oct 11 04:10 PM
Szalay Aladar10% OwnerOct 05 '23Sale24.9314,251355,2291,427,236Oct 10 04:49 PM
Szalay Aladar10% OwnerOct 03 '23Sale25.4975,6901,929,2251,441,487Oct 04 06:43 PM
Szalay Aladar10% OwnerSep 28 '23Sale24.122,28955,2111,517,177Sep 29 04:34 PM
Szalay Aladar10% OwnerSep 27 '23Sale24.4711,257275,4591,519,466Sep 29 04:34 PM
Yu YongVP, Clinical Trial OperationsSep 26 '23Option Exercise6.005,20031,200111,335Sep 27 04:10 PM
Szalay Aladar10% OwnerSep 26 '23Sale23.7929,805709,1771,530,723Sep 27 04:33 PM
Yu YongVP, Clinical Trial OperationsSep 26 '23Sale23.565,200122,528106,135Sep 27 04:10 PM
Szalay Aladar10% OwnerSep 25 '23Sale25.7712,458321,0041,560,528Sep 27 04:33 PM
Szalay Aladar10% OwnerSep 22 '23Sale27.339,042247,1231,572,986Sep 25 06:30 PM
Szalay Aladar10% OwnerSep 21 '23Sale28.467,549214,8781,582,028Sep 25 06:30 PM
Ryder SeanGeneral CounselSep 20 '23Option Exercise6.0010,00060,00010,572Sep 21 04:30 PM
Yu YongVP, Clinical Trial OperationsSep 20 '23Option Exercise6.006,00036,000112,135Sep 21 04:35 PM
Ryder SeanGeneral CounselSep 20 '23Sale30.0010,000300,000572Sep 21 04:30 PM
Yu YongVP, Clinical Trial OperationsSep 20 '23Sale27.966,000167,786106,135Sep 21 04:35 PM
Szalay Aladar10% OwnerSep 19 '23Sale26.4532,167850,9420Sep 20 04:48 PM
Szalay Aladar10% OwnerSep 18 '23Sale23.2930,292705,6495,000Sep 20 04:48 PM
Thomas JohnDirectorSep 18 '23Sale24.993,33483,317475,793Sep 18 08:12 PM
Yu YongVP, Clinical Trial OperationsSep 15 '23Option Exercise6.0010,40062,400116,535Sep 18 08:13 PM
Yu YongVP, Clinical Trial OperationsSep 15 '23Sale21.8910,400227,630106,135Sep 18 08:13 PM
Thomas JohnDirectorSep 15 '23Sale21.903,33372,996479,127Sep 18 08:12 PM
Szalay Aladar10% OwnerSep 14 '23Sale22.0725,276557,80635,292Sep 15 04:19 PM
Yu YongVP, Clinical Trial OperationsSep 13 '23Sale21.1429,800629,927106,135Sep 15 08:06 PM
Szalay Aladar10% OwnerSep 13 '23Sale21.4419,032408,09360,568Sep 15 04:19 PM
Smither John WDirectorSep 13 '23Sale20.7890018,7026,920Sep 14 08:18 PM
Szalay Aladar10% OwnerSep 12 '23Sale22.2620,265451,16779,600Sep 13 07:04 PM
Szalay Aladar10% OwnerSep 11 '23Sale22.2232,351718,70299,865Sep 13 07:04 PM
Szalay Aladar10% OwnerSep 08 '23Sale23.1724,831575,332132,216Sep 11 07:05 PM
Szalay Aladar10% OwnerSep 07 '23Sale24.3712,446303,268157,047Sep 11 07:05 PM
Yu YongVP, Clinical Trial OperationsAug 30 '23Sale24.7019,800489,060135,935Aug 30 07:22 PM
Zindrick ThomasPresident and CEOAug 18 '23Sale23.738,349198,12214,651Aug 22 04:13 PM
Yu YongVP, Clinical Trial OperationsAug 18 '23Sale23.733,26577,478155,735Aug 22 04:14 PM
Cappello JosephVP, Pharmaceutical DevelopmentAug 18 '23Sale23.733,26577,4785,735Aug 22 04:15 PM
Samuelson DougChief Financial OfficerAug 18 '23Sale23.731,29730,7782,303Aug 22 04:17 PM
Smalling RalphHead of RegulatoryAug 18 '23Sale23.7393522,1882,065Aug 22 04:18 PM
Jewett CarolineHead of QualityAug 18 '23Sale23.7351512,2211,135Aug 22 04:18 PM
Ryder SeanGeneral CounselAug 18 '23Sale23.733287,783572Aug 22 04:16 PM